BRIEF — Kyverna Therapeutics Reports Positive One — Year Data Demonstrating Durable Clinical Responses And Favorable Safety Profile For Miv — Cel In Stiff Person Syndrome And Generalized Myasthenia Gravis

Sept 24 (Reuters) — Kyverna Therapeutics, Inc.: Kyverna Therapeutics Reports Positive One-year Data Demonstrating Durable Clinical Responses And Favorable Safety Profile For Miv-cel In Stiff Person Syndrome And Generalized Myasthenia Gravis Kyverna Therapeutics, - Miv-cel Well-tolerated In Gmg Trial With No High-grade Crs, Icans, Or Iec-hs Kyverna Therapeutics, - Phase 3 Kysa-6 Trial Enrollment Expected To Be Completed In Mid-2027 Source text:... Further company coverage: KYTX.O (Reuters.Briefs@thomsonreuters.com;)